medigraphic.com
ISSN 1561-302X (Print)

2021, Number 3

<< Back Next >>

Rev cubana med 2021; 60 (3)

Clinical description and oxidative stress markers in patients with lung cancer treated with polychemotherapy

Fernández GS, Riverón FG, López IY, González DD, Fariñas RL, Lemus MG, Castillo CY

Language: Spanish
References: 20
Page: 1-12
PDF size: 332.86 Kb.


ABSTRACT

Introduction: Oncological treatments used in lung cancer, particularly polychemotherapy, promote cytotoxicity and the release of certain reactive oxygen species in their mechanism of action.
Objective: To describe patients with lung cancer according to oxidative stress and antioxidant defense markers at the time of diagnosis and after the end of treatment with polychemotherapy.
Methods: An analytical, prospective study was carried out in 86 cases. They were distributed into two groups: subjects diagnosed with lung cancer (n= 52) and healthy subjects (n= 34) at the Pneumological Hospital from May 2016 to May 2018.
Results: The male subjects predominated (63.5%) and 55.8% were over 60 years old. The most frequent histological type was adenocarcinoma (57.7%) and 61.5% used the cisplatin and etoposide chemotherapy modality. Lung cancer patients showed higher endogenous oxidative damage to lipids and proteins (40.4% and 28.8%) respectively, while 63.5% kept normal plasma concentrations of total peroxides. In 40.4% of the patients, the enzymatic defense activities of superoxide dismutase, catalase and glutathione peroxidase increased, which tended to normal (63.5% and 48.0%) respectively. 76.9% reached normal levels of glutathione s-transferase after oncospecific treatment.
Conclusions: Chemotherapy is related to exacerbation of oxidative stress and a decrease in the antioxidant defense system.


REFERENCES

  1. National Comprehensive Cancer Network (NCCN). Non-small cell lung cancer guidelines. Versión 6. 2017[acceso: 20/03/2020]. Disponible en: Disponible en: http://www.nccn.org/professionals/physician gls/f guidelines.asp

  2. Ministerio de Salud Pública. Colectivo de autores. Anuario Estadístico de Salud 2016. La Habana: Minsap. 2017[acceso: 20/03/2020]. Disponible en: Disponible en: https://files.sld.cu/dne/files/2017/05/Anuario_Estad%C3%ADstico_de_Salud_e_2016_edici%C3%B3n_2017.pdf

  3. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends an update. Cancer Epidemiology and Prevention Biomarkers. 2016[acceso: 20/03/2020];25:16-27. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/26667886/

  4. Kota VR, Sanjay Srivastava Sharad SS. Lipid Peroxidation Products in Human Health and Disease 2016. Oxidative Medicine and Cellular Longevity. 2017;2. Disponible en: https://doi.org/10.1155/2017/2163285

  5. Klaunig JE. Oxidative Stress and Cancer. Curr Pharm Des. 2018[acceso: 20/03/2020];24(40):4771-78. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/30767733/

  6. Zubrod CG, Lopringi Cl. Prospective evaluation of prognostic variables from patients completed questionnaires. Performance Status Series. J Clin Oncol. 1994[acceso: 20/03/2020];12:601-07. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/8120560/

  7. Pérez C, Riverón G, Fernández I, del Castillo NP, Martínez O, Gutiérrez R, et al. Marcadores de estrés oxidativo y genotoxicidad en trabajadores cubanos con exposición ocupacional prolongada al plomo. Revista Cubana de Salud y Trabajo. 2015[acceso: 24/03/2020];16(3):20-25. Disponible en: Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=63275#

  8. Burstein HJ, Krilov J, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, et al. Clinical cancer advances 2017: Anual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2017[acceso: 24/03/2020];35:1341-67. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/28148207/

  9. González Díaz D, Díaz Toledo M, Díaz Garrido D, Fernández García S. Respuesta al tratamiento con Poliquimioterapia en pacientes con carcinoma no microcítico. Rev Cubana Med. 2020[acceso: 24/05/2020];59(2). Disponible en: Disponible en: http://www.revmedicina.sld.cu/index.php/med/article/view/1358

  10. Kannemann A, Muñiz A, Playá G, López Brea M, García A, Arangüena L, et al. Carcinoma no microcítico de pulmón localmente avanzado tratado con quimioradioterapia en el Hospital Universitario Marqués de Valdecilla (HUMV) en 2013 y 2014: Resultados de toxicidad y supervivencia. Rev Med Valdecilla. 2017[acceso: 24/03/2020];2(1). Disponible en: Disponible en: http://www.humv.es/revista-valdecilla/2_1/rev_med_valdecilla_2_1_completa.pdf

  11. Parente I, Abal J, García MJ, García JM, Acuña A, Velásquez PM. Cáncer de pulmón en mujeres, comparativo con hombres: análisis de los casos diagnosticados en el Complexo Hospitalario de Ourense entre 1999 y 2006. Arch Bronconeumol. 2011[acceso: 24/03/2020];47:61-5. Disponible en: Disponible en: https://archbronconeumol.org/en-cancer-pulmon-mujeres-comparativo-con-articulo-S0300289610003327

  12. Rodríguez Cascaret A, Martín Rodríguez A, Hernández Castellanos K. Concordancia clínica, tomográfica y anatomopatológica en el cáncer de pulmón. Medisan. 2011[acceso: 24/03/2020];15(5). Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192011000500012

  13. Senan S, Brade A, Wang L, Vansteenkisten J, Dakhil S, Biesma B, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016[acceso: 24/03/2020];34:953-62. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/26811519/

  14. Wakabayashi T, Kawashima T, Matsuzawa Y. Evaluation of reactive oxygen metabolites in patients with non-small cell lung cancer after chemotherapy. Multidiscip Respir Med. 2014[acceso: 24/03/2020];9(1):44. Disponible en: Disponible en: https://www.researchgate.net/publication/265299686_Evaluation_of_reactive_oxygen_metabolites_in_patients_with_non-small_cell_lung_cancer_after_chemotherapy

  15. Srivastava AN, Gupta A, Srivastava S, Natu SM, Mittal B, Negi MP, et al. Cisplatin combination chemotherapy induces oxidative stress in advance non-small cell lung cancer patients. Asian Pac J Cancer Prev. 2010[acceso: 27/03/2020];11:465-71. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/20843135/

  16. Zabłocka-Słowińska K, Płaczkowska S, Skórska K, Prescha A, Pawełczyk K, Porębska I, et al. Oxidative stress in lung cancer patients is associated with altered serum markers of lipid metabolism. PLoS ONE. 2019;14(4):e0215246. https://doi.org/10.1371/journal.pone.0215246

  17. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014[acceso: 20/03/2020];740:364-78. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/25058905/

  18. Makovec T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol. 2019[acceso: 20/03/2020];53(2):148-158. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572495/

  19. Gęgotek A, Nikliński J, Žarković N, Žarković K, Waeg G, Łuczaj W, et al. Lipid mediators involved in the oxidative stress and antioxidant defence of human lung cancer cells. Redox Biology. 2016[acceso: 20/03/2020];9:210-9. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S2213231716301252

  20. Gill JG, Piskounova E, Morrison SJ. Cancer, Oxidative Stress, and Metastasis. Cold Spring Harb Symp Quant Biol. 2016[acceso: 20/03/2020];81:163-75. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/28082378/




2020     |     www.medigraphic.com